Aytu BioPharma, Inc. AYTU
2.28
(0.03)
(1.30%)
as of 25 Sep
- Market cap
- $25.1M
- P/E
- 0.0×
Follow AYTU
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(49.33%) | (108.72%) | (97.24%) | (52.55%) | |
| (10.86%) | (20.52%) | (28.87%) | (12.44%) | ||
ROIC |
(29.63%) | (106.20%) | (31.33%) | (19.99%) | |
Return on Tangible Assets |
(83.70%) | (218.98%) | (438.80%) | (190.36%) | |
Average Days of Receivables |
190.39 | 180.19 | 157.93 | 144.42 | |
Free Cash Flow per Share |
(0.14) | (0.06) | 0.15 | 0.26 | |
Free Cash Flow |
(1.36) | (0.55) | 1.58 | 3.24 | |
Capital Expenditures |
— | 0.04 | (0.10) | (0.05) | |
Piotroski F-Score |
3.00 | 3.00 | 3.00 | 3.00 | |
| Other line items | |||||
Cash ROIC |
(1.65%) | (0.91%) | 2.01% | 4.17% | |
Accounts Receivable Turnover |
2.26 | 2.22 | 1.88 | 2.13 | |
Accounts Payable Turnover |
1.60 | 1.60 | 1.58 | 1.90 | |
Inventory Turnover |
1.89 | 2.10 | 2.15 | 2.27 | |
Average Days of Payables |
218.00 | 250.58 | 241.93 | 198.47 | |
Days of Inventory on Hand |
178.40 | 152.12 | 136.58 | 120.66 | |
Tax Rate |
0.00 | 0.00 | 0.01 | 0.03 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 1.59% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
59.26% | 62.41% | 71.90% | 74.07% | |
Share Based Compensation of Revenue |
0.81% | 1.04% | 1.16% | 1.20% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.10 | 0.02 | (0.05) | (0.23) | |
Depreciation/Fixed assets |
9.91 | 9.40 | 10.77 | 10.50 | |
Capex/Depreciation |
0.00 | 0.01 | (0.02) | (0.01) | |
Revenue per Share |
6.75 | 6.24 | 5.38 | 4.67 | |
Operating CF per Share |
(0.14) | (0.06) | 0.16 | 0.27 | |
Capex per Share |
0.00 | 0.00 | (0.01) | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
(20.52%) | (39.02%) | (60.17%) | (24.76%) |
Columns are period end dates · fundamentals updated 24 Sep 2026